研究方向:
急性淋巴细胞白血病化疗耐药性的表观遗传学调控机理研究
Mechanisms of Epigenetic Regulation of Chemo-Resistance in Acute Lymphoblastic Leukemia
主要成果:
井多辉博士，2004年本科毕业于清华大学生物科学与技术系。而后就读德国德累斯顿工业大学，于2010年获得内科学医学博士学位。2011至2019年，井博士受聘于澳大利亚悉尼儿童癌症研究所，主要从事急性淋巴细胞白血病（ALL）方面的研究。他将多种前沿技术应用于ALL移植瘤PDX的小鼠模型，例如ChIP-seq、ATAC-seq、CRISPR/Cas9、3C/HiC等，开发了一个集多组学基因检测和临床前药物检测于一体的研究平台（Blood 2015，第一作者; Cancer Cell 2018，第一作者兼通讯作者）。这些文章详细探讨了ALL化疗耐药性的分子机理，特别是Cancer Cell文章被选为了该杂志2018年12月的封面文章，彰显了这些工作的国际影响力。此外，他还开发并拓展了血液原代细胞的体外和体内实验模型（Haematologica 2010 & 2012，第一作者），并为多种药物的研发提供了技术支持，包括使用生物荧光技术活体监测ALL MRD细胞（Clin Cancer Res 2017）和使用三合一单细胞测序技术评估新药的疗效（Cancer Cell 2019）。论文总引用量超过800次, 平均每篇文章被引用50次以上。过去五年（2015至2019年），井博士作为第一负责人共获得166万澳元（约合人民币800万元）的六项澳大利亚科研经费支持，包括澳大利亚国家健康科研基金（$653,880，约合人民币320万元）和新南威尔士州癌症研究院的Fellowship（$606,479，约合人民币303万元）。
2019年11月井博士放弃所有在研的澳大利亚科研经费，全职回国，入职上海交通大学医学院附属瑞金医院上海血液学研究所，担任课题组长的职务，入选了上海市海外高层次人才计划。

Dr Duohui Jing graduated from Tsinghua University, China in 2004, and undertook doctoral study on Internal Medicine at Technische Universität Dresden, Germany. In 2011, he relocated from Germany to Australia and started his research on molecular mechanisms of chemo-resistance in acute lymphoblastic leukaemia (ALL). He has established several cutting-edge techniques such as ChIP-seq, ATAC-seq, CRISPR/Cas9, 3C/HiC and more, in ALL patient-derived xenografts. This led to the development of a novel platform that integrated multiple whole-genome approaches with glucocorticoid-based chemotherapy (Blood, first author, 2015; Cancer Cell, first & co-corresponding author, 2018). His work has been featured as the cover story of Cancer Cell and the subject of commentaries in Blood and Cancer Cell, which indicates a substantial recognition in the field. Furthermore, Dr Jing has established an ex vivo co-culture system for maintaining human primary hematopoietic stem cells (Haematologica, first author, 2010 & 2012), and provided technical support for assessing drug efficacy in vivo using bioluminescence imaging (Clin Cancer Res 2017) and single cell profiling (Cancer Cell 2019). His publications have received >900 citations at an average of over 50/article. Over the past 5 years (2015-2019), Dr Jing, as Chief Investigator A, has been awarded 6 grants of a total $1.66M in Australia, including the Australia National Health and Medical Research Council (NHMRC) Idea Grant ($653,880) and Cancer Institute NSW Early Career Fellowship ($606,479).
In November 2019, Dr. Jing gave up all research funding in Australia, returned to China full-time, joined the Shanghai Institute of Hematology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, and appointed as a group leader. Since then, Dr Jing was awarded several honorary titles.
工作经历:
2019.11-至今，研究员，课题组长，上海交通大学医学院附属瑞金医院上海血液学研究所；Honorary Visiting Professor，澳大利亚悉尼科技大学（UTS）
2019-present, Professor/Group Leader, Shanghai Institute of Hematology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Honorary Visiting Professor, University of Technology Sydney（UTS）

2016-2019，Senior Research Officer，澳大利亚新南威尔士大学儿童癌症研究所（Children's Cancer Institute, UNSW, Australia）

2011-2015，Research Officer，澳大利亚新南威尔士大学儿童癌症研究所（Children's Cancer Institute, UNSW, Australia）
荣誉:
2019 澳大利亚新南威尔士大学高质量科研论文奖（Promoting High Quality Research Papers Scheme – Key Incentive 1）
2018 杰出科研成就奖（Research Excellence Award），澳大利亚华人生物医学科学家协会
2017 杰出贡献奖（Service Excellence Award），澳大利亚华人生物医学科学家协会
2016 儿童癌症研究所和巴尔内夫斯基金会联合学术交流基金（Balnaves Foundation and Children's Cancer Institute Travel Grant）。
2016 Roche青年学者旅行基金奖（Roche New Investigator Travel Grant）, 澳大利亚白血病研究新方向会议, 昆士兰努萨
2015 Illumina青年学者报告奖（Illumina Early Career Researcher Speaker Awards – second place）, 澳大利亚表观遗传学会议，塔斯马尼亚霍巴特

主要论文:
(1) Jing, D*; Huang, Y; Liu, X; Sia, K. C. S; Zhang, J. C; Tai, X; Wang, M; Toscan, C. E; McCalmont, H; Evans, K; Mayoh, C; Poulos, R. C; Span, M; Mi, J; Zhang, C; Wong, J. W. H; Beck, D; Pimanda, J. E; Lock, R. B.*; Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia , Cancer Cell, 2018, 34(6): 906-921 e8.
(2) Jing, D; Bhadri, V. A; Beck, D; Thoms, J. A; Yakob, N. A; Wong, J. W; Knezevic, K; Pimanda, J. E; Lock, R. B.*; Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells , Blood, 2015, 125(2): 273-283.
(3) Jing, D#; Wobus, M#; Poitz, D. M; Bornhauser, M; Ehninger, G; Ordemann, R.*; Oxygen tension plays a critical role in the hematopoietic microenvironment in vitro, Haematologica, 2012, 97(3): 331-339.
(4) Jing, D; Fonseca, A. V; Alakel, N; Fierro, F. A; Muller, K; Bornhauser, M; Ehninger, G; Corbeil, D; Ordemann, R.*; Hematopoietic stem cells in co-culture with mesenchymal stromal cells--modeling the niche compartments in vitro, Haematologica, 2010, 95(4): 542-550.
(5) Jing, D#; Oelschlaegel, U#; Ordemann, R; Holig, K; Ehninger, G; Reichmann, H; Ziemssen, T; Bornhauser, M.*; CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function , Bone Marrow Transplantation, 2010, 45(10): 1489-1496.
(6) Jing, D#, Alakel, N#, Bornhauser, M, Ehninger, G & Ordemann, R. SDF-1/CXCR4 blockade to mobilize hematopoietic progenitor cells from the placenta. Bone Marrow Transplantation. 2010, 45:1661-1662.
(7) El-Hoss, J#; Jing, D#, et al (2016) A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. Oncotarget, 37: 60475-60490.
(8) Krivtsov，et al... Jing，D, et al (2019) A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell, 36, 660-673 e611.